Skip to main content
. 2003 May 27;88(11):1785–1792. doi: 10.1038/sj.bjc.6600982

Figure 4.

Figure 4

Apaf-1-dependent cytotoxicity and caspase-activation by rML-treatment. (A) Apaf-1-wild-type and Apaf-1-deficient MEFs were treated with rML (0–0.5 ng ml−1) and cell viability was determined by trypan blue exclusion 24 h after treatment. (B) Formation of active caspase-3 was determined in cytosolic extracts 18 h following treatment with rML using a specific antibody recognising the cleaved caspase-3 subunit.